MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

April 09, 2015
Breast Cancer
Christine Gresik, MD

Naperville, Plainfield

This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct.  MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body.  MRI may help find and diagnose patients with breast cancer.  It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence.  Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.

Sponsor: Eastern Cooperative Oncology Group (ECOG)

  • Unilateral ductal carcinoma in situ with no evidence of microinvasive or invasive disease 
  • No previous same breast invasive breast cancer or DCIS
  • No known deleterious mutations in breast cancer (BRCA) genes
  • No hormonal therapy (i.e., tamoxifen, raloxifene, and/or aromatase inhibitors) for prevention of breast cancer within 3 months of the biopsy documenting DCIS
  • No chemotherapy for cancer within 6 months prior to registration
  • Suitable to undergo MRI and receive the contrast agent gadolinium
  • No prior MRI of the breasts within the 6 months prior to registration

10-12 years

Accepting Participants
Kathy Seymour, BSN